Introducing Lonza’s AAV suspension transient transfection platform to de-risk your path to clinic
Sponsor
Adeno associated viral vector (AAV) is the delivery vehicle of choice for potentially curative in vivo gene therapy. Following a couple of landmark approvals, this field has experienced accelerated pipeline growth and investor interest in the past five years. Currently AAV therapies are predominantly targeting rare genetic disorders for which the patient population is often limited. As a result, drug developers feel immense pressure to be first to market to commercialize their therapies.
In this Webinar, Lonza CGT will focus on a robust, streamlined platform process for fast production of AAV using Lonza’s clonal suspension HEK293 cell line, proprietary plasmids to ensure high productivity and in process analytics enabling enhanced full to empty capsid ratio. We will further discuss Lonza’s approach for building reliable, de-risked path to clinic to avoid unforeseen costs and compliance-related delays.
- Speed to clinic with a de-risked, robust, scalable platform process for AAV production
- High AAV productivity and yield with Lonza’s proprietary plasmids (Rep/cap + pHelper) and clonal HEK293 cell line
- Full/empty analytics enabling USP and DSP optimization at early stages/small scale
- Pre-qualified platform assays
SPEAKERS
You might also like
Same-section spatial multiomics: a platform for detailed analysis of the solid tumor TME
Specifications don’t tell the whole story: how to choose GMP process and QC equipment
Revolutionary innovations are underway to industrialize cell and gene therapies
Quadplex dPCR as a tool to analyze genome integrity and heterogeneity in gene therapy drug products
